A Multiple-Dose Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2022-07-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of study drug known as LY3209590
compared to insulin glargine administered in participants with type 2 diabetes mellitus
(T2DM). Side effects and tolerability will be documented. The study will last almost six
months and 21 visits for each participant including screening period.